Annual FCF
-$30.68 M
-$3.83 M-14.28%
December 31, 2023
Summary
- As of February 8, 2025, AVTX annual free cash flow is -$30.68 million, with the most recent change of -$3.83 million (-14.28%) on December 31, 2023.
- During the last 3 years, AVTX annual FCF has risen by +$9.92 million (+24.44%).
- AVTX annual FCF is now -344.36% below its all-time high of $12.56 million, reached on December 31, 2017.
Performance
AVTX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$11.53 M
+$4.76 M+29.21%
September 30, 2024
Summary
- As of February 8, 2025, AVTX quarterly free cash flow is -$11.53 million, with the most recent change of +$4.76 million (+29.21%) on September 30, 2024.
- Over the past year, AVTX quarterly FCF has increased by +$4.76 million (+29.21%).
- AVTX quarterly FCF is now -160.30% below its all-time high of $19.12 million, reached on September 30, 2017.
Performance
AVTX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$36.78 M
-$4.69 M-14.62%
September 30, 2024
Summary
- As of February 8, 2025, AVTX TTM free cash flow is -$36.78 million, with the most recent change of -$4.69 million (-14.62%) on September 30, 2024.
- Over the past year, AVTX TTM FCF has dropped by -$4.69 million (-14.62%).
- AVTX TTM FCF is now -331.12% below its all-time high of $15.91 million, reached on June 30, 2018.
Performance
AVTX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
AVTX Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -14.3% | +29.2% | -14.6% |
| 3 y3 years | +24.4% | -192.6% | -37.0% |
| 5 y5 years | -730.9% | -51.3% | -37.0% |
AVTX Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -14.3% | +56.8% | -302.7% | +32.6% | -90.3% | +48.2% |
| 5 y | 5-year | -58.2% | +56.8% | -302.7% | +39.9% | -90.3% | +48.2% |
| alltime | all time | -344.4% | +56.8% | -160.3% | +39.9% | -331.1% | +48.2% |
Avalo Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$11.53 M(-29.2%) | -$36.78 M(+14.6%) |
| Jun 2024 | - | -$16.28 M(+162.5%) | -$32.09 M(+19.6%) |
| Mar 2024 | - | -$6.20 M(+124.2%) | -$26.83 M(-12.5%) |
| Dec 2023 | -$30.68 M(+14.3%) | -$2.77 M(-59.5%) | -$30.68 M(-3.7%) |
| Sep 2023 | - | -$6.84 M(-38.0%) | -$31.85 M(+64.8%) |
| Jun 2023 | - | -$11.03 M(+9.7%) | -$19.33 M(-7.2%) |
| Mar 2023 | - | -$10.05 M(+155.1%) | -$20.83 M(-22.4%) |
| Dec 2022 | -$26.85 M(-62.2%) | -$3.94 M(-169.3%) | -$26.85 M(-32.9%) |
| Sep 2022 | - | $5.69 M(-145.4%) | -$40.02 M(-35.5%) |
| Jun 2022 | - | -$12.53 M(-22.0%) | -$62.07 M(-9.7%) |
| Mar 2022 | - | -$16.07 M(-6.1%) | -$68.73 M(-3.2%) |
| Dec 2021 | -$71.00 M(+74.9%) | -$17.11 M(+4.5%) | -$71.00 M(+4.0%) |
| Sep 2021 | - | -$16.37 M(-14.7%) | -$68.27 M(+7.0%) |
| Jun 2021 | - | -$19.19 M(+4.6%) | -$63.83 M(+20.0%) |
| Mar 2021 | - | -$18.34 M(+27.6%) | -$53.20 M(+31.0%) |
| Dec 2020 | -$40.60 M(+109.3%) | -$14.38 M(+20.5%) | -$40.60 M(+45.5%) |
| Sep 2020 | - | -$11.93 M(+39.5%) | -$27.91 M(+18.3%) |
| Jun 2020 | - | -$8.55 M(+49.1%) | -$23.59 M(+8.0%) |
| Mar 2020 | - | -$5.74 M(+241.5%) | -$21.85 M(+12.6%) |
| Dec 2019 | -$19.40 M | -$1.68 M(-77.9%) | -$19.40 M(-3.9%) |
| Sep 2019 | - | -$7.62 M(+11.9%) | -$20.19 M(+53.6%) |
| Jun 2019 | - | -$6.81 M(+107.1%) | -$13.15 M(+96.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$3.29 M(+32.8%) | -$6.68 M(+80.9%) |
| Dec 2018 | -$3.69 M(-129.4%) | -$2.48 M(+328.6%) | -$3.69 M(-2.4%) |
| Sep 2018 | - | -$577.50 K(+69.7%) | -$3.78 M(-123.8%) |
| Jun 2018 | - | -$340.40 K(+13.6%) | $15.91 M(+9.8%) |
| Mar 2018 | - | -$299.60 K(-88.3%) | $14.49 M(+15.4%) |
| Dec 2017 | $12.56 M(-185.9%) | -$2.56 M(-113.4%) | $12.56 M(+10.2%) |
| Sep 2017 | - | $19.12 M(-1186.8%) | $11.40 M(-202.1%) |
| Jun 2017 | - | -$1.76 M(-21.4%) | -$11.16 M(-15.0%) |
| Mar 2017 | - | -$2.24 M(-39.9%) | -$13.13 M(-10.1%) |
| Dec 2016 | -$14.61 M(+43.4%) | -$3.72 M(+8.2%) | -$14.61 M(+1.2%) |
| Sep 2016 | - | -$3.44 M(-7.8%) | -$14.43 M(+12.5%) |
| Jun 2016 | - | -$3.73 M(+0.4%) | -$12.83 M(+18.5%) |
| Mar 2016 | - | -$3.72 M(+4.7%) | -$10.83 M(+6.3%) |
| Dec 2015 | -$10.18 M(-34.5%) | -$3.55 M(+93.4%) | -$10.18 M(-4.0%) |
| Sep 2015 | - | -$1.83 M(+6.0%) | -$10.60 M(-33.3%) |
| Jun 2015 | - | -$1.73 M(-43.6%) | -$15.89 M(-3.1%) |
| Mar 2015 | - | -$3.07 M(-22.6%) | -$16.39 M(+5.5%) |
| Dec 2014 | -$15.54 M(+34.9%) | -$3.97 M(-44.3%) | -$15.54 M(+34.3%) |
| Sep 2014 | - | -$7.12 M(+218.1%) | -$11.57 M(+160.0%) |
| Jun 2014 | - | -$2.24 M(+1.2%) | -$4.45 M(+101.2%) |
| Mar 2014 | - | -$2.21 M | -$2.21 M |
| Dec 2013 | -$11.51 M | - | - |
FAQ
- What is Avalo Therapeutics annual free cash flow?
- What is the all time high annual FCF for Avalo Therapeutics?
- What is Avalo Therapeutics annual FCF year-on-year change?
- What is Avalo Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Avalo Therapeutics?
- What is Avalo Therapeutics quarterly FCF year-on-year change?
- What is Avalo Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Avalo Therapeutics?
- What is Avalo Therapeutics TTM FCF year-on-year change?
What is Avalo Therapeutics annual free cash flow?
The current annual FCF of AVTX is -$30.68 M
What is the all time high annual FCF for Avalo Therapeutics?
Avalo Therapeutics all-time high annual free cash flow is $12.56 M
What is Avalo Therapeutics annual FCF year-on-year change?
Over the past year, AVTX annual free cash flow has changed by -$3.83 M (-14.28%)
What is Avalo Therapeutics quarterly free cash flow?
The current quarterly FCF of AVTX is -$11.53 M
What is the all time high quarterly FCF for Avalo Therapeutics?
Avalo Therapeutics all-time high quarterly free cash flow is $19.12 M
What is Avalo Therapeutics quarterly FCF year-on-year change?
Over the past year, AVTX quarterly free cash flow has changed by +$4.76 M (+29.21%)
What is Avalo Therapeutics TTM free cash flow?
The current TTM FCF of AVTX is -$36.78 M
What is the all time high TTM FCF for Avalo Therapeutics?
Avalo Therapeutics all-time high TTM free cash flow is $15.91 M
What is Avalo Therapeutics TTM FCF year-on-year change?
Over the past year, AVTX TTM free cash flow has changed by -$4.69 M (-14.62%)